183 related articles for article (PubMed ID: 18782439)
1. Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of Salmon Calcitonin.
Karsdal MA; Byrjalsen I; Riis BJ; Christiansen C
BMC Clin Pharmacol; 2008 Sep; 8():5. PubMed ID: 18782439
[TBL] [Abstract][Full Text] [Related]
2. Influence of food intake on the bioavailability and efficacy of oral calcitonin.
Karsdal MA; Byrjalsen I; Azria M; Arnold M; Choi L; Riis BJ; Christiansen C
Br J Clin Pharmacol; 2009 Apr; 67(4):413-20. PubMed ID: 19371314
[TBL] [Abstract][Full Text] [Related]
3. Investigations of inter- and intraindividual relationships between exposure to oral salmon calcitonin and a surrogate marker of pharmacodynamic efficacy.
Karsdal MA; Byrjalsen I; Henriksen K; Riis BJ; Christiansen C
Eur J Clin Pharmacol; 2010 Jan; 66(1):29-37. PubMed ID: 19813008
[TBL] [Abstract][Full Text] [Related]
4. The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study.
Karsdal MA; Byrjalsen I; Henriksen K; Riis BJ; Lau EM; Arnold M; Christiansen C
Osteoarthritis Cartilage; 2010 Feb; 18(2):150-9. PubMed ID: 19747581
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover.
Tankó LB; Bagger YZ; Alexandersen P; Devogelaer JP; Reginster JY; Chick R; Olson M; Benmammar H; Mindeholm L; Azria M; Christiansen C
J Bone Miner Res; 2004 Sep; 19(9):1531-8. PubMed ID: 15312255
[TBL] [Abstract][Full Text] [Related]
6. A pharmacokinetic and pharmacodynamic comparison of synthetic and recombinant oral salmon calcitonin.
Karsdal MA; Byrjalsen I; Henriksen K; Riis BJ; Christiansen C
J Clin Pharmacol; 2009 Feb; 49(2):229-34. PubMed ID: 19179298
[TBL] [Abstract][Full Text] [Related]
7. Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin.
Karsdal MA; Byrjalsen I; Riis BJ; Christiansen C
BMC Clin Pharmacol; 2008 Dec; 8():12. PubMed ID: 19055791
[TBL] [Abstract][Full Text] [Related]
8. Biochemical markers identify influences on bone and cartilage degradation in osteoarthritis--the effect of sex, Kellgren-Lawrence (KL) score, body mass index (BMI), oral salmon calcitonin (sCT) treatment and diurnal variation.
Karsdal MA; Byrjalsen I; Bay-Jensen AC; Henriksen K; Riis BJ; Christiansen C
BMC Musculoskelet Disord; 2010 Jun; 11():125. PubMed ID: 20565725
[TBL] [Abstract][Full Text] [Related]
9. Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials.
Karsdal MA; Henriksen K; Bay-Jensen AC; Molloy B; Arnold M; John MR; Byrjalsen I; Azria M; Riis BJ; Qvist P; Christiansen C
J Clin Pharmacol; 2011 Apr; 51(4):460-71. PubMed ID: 20660294
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of salmon calcitonin (sCT) enteric-coated capsule for enhanced absorption and GI tolerability in rats.
Wu L; Zhang G; Lu Q; Sun Q; Wang M; Li N; Gao Z; Sun Y; Li T; Han D; Yu X; Wang L; Sun W; Zhao D; Wu Y; Lu Y; Chen X
Drug Dev Ind Pharm; 2010 Mar; 36(3):362-70. PubMed ID: 19719396
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis.
Bandeira L; Lewiecki EM; Bilezikian JP
Expert Opin Drug Metab Toxicol; 2016 Jun; 12(6):681-9. PubMed ID: 27070719
[TBL] [Abstract][Full Text] [Related]
12. Encapsulation into PEG-liposomes does not improve the bioavailability of pulmonary delivered salmon calcitonin.
Swaminathan J; Gobbo OL; Tewes F; Healy AM; Ehrhardt C
J Aerosol Med Pulm Drug Deliv; 2014 Feb; 27(1):1-11. PubMed ID: 24252061
[TBL] [Abstract][Full Text] [Related]
13. Coated minispheres of salmon calcitonin target rat intestinal regions to achieve systemic bioavailability: Comparison between intestinal instillation and oral gavage.
Aguirre TAS; Aversa V; Rosa M; Guterres SS; Pohlmann AR; Coulter I; Brayden DJ
J Control Release; 2016 Sep; 238():242-252. PubMed ID: 27480451
[TBL] [Abstract][Full Text] [Related]
14. Effect of chitosan on the intranasal absorption of salmon calcitonin in sheep.
Hinchcliffe M; Jabbal-Gill I; Smith A
J Pharm Pharmacol; 2005 Jun; 57(6):681-7. PubMed ID: 15969922
[TBL] [Abstract][Full Text] [Related]
15. Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers.
Buclin T; Cosma Rochat M; Burckhardt P; Azria M; Attinger M
J Bone Miner Res; 2002 Aug; 17(8):1478-85. PubMed ID: 12162502
[TBL] [Abstract][Full Text] [Related]
16. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
Binkley N; Bolognese M; Sidorowicz-Bialynicka A; Vally T; Trout R; Miller C; Buben CE; Gilligan JP; Krause DS;
J Bone Miner Res; 2012 Aug; 27(8):1821-9. PubMed ID: 22437792
[TBL] [Abstract][Full Text] [Related]
17. Effect of nasal salmon calcitonin on calcium and bone metabolism.
Thamsborg G
Dan Med Bull; 1999 Apr; 46(2):118-26. PubMed ID: 10327295
[TBL] [Abstract][Full Text] [Related]
18. Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis.
Bagger YZ; Tankó LB; Alexandersen P; Karsdal MA; Olson M; Mindeholm L; Azria M; Christiansen C
Bone; 2005 Sep; 37(3):425-30. PubMed ID: 16005273
[TBL] [Abstract][Full Text] [Related]
19. Calcitonin load test to assess the efficacy of salmon calcitonin.
Stepan JJ; Zikán V
Clin Chim Acta; 2003 Oct; 336(1-2):49-55. PubMed ID: 14500034
[TBL] [Abstract][Full Text] [Related]
20. Plasma type 1 collagen cross-linked C-telopeptide: a sensitive marker of acute effects of salmon calcitonin on bone resorption.
Zikán V; Stepan JJ
Clin Chim Acta; 2002 Feb; 316(1-2):63-9. PubMed ID: 11750275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
